RNAZ - Cash Flow Statement - TransCode Therapeutics, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018
OPERATING CASH FLOW
Net Income	(16.8)	(18.5)	(17.6)	(6.8)	(2.3)	(0.6)	(0.5)
Depreciation & Amortization	0.5	0.5	98.6 K	42.5 K	0	0	0
Deferred Income Tax	0	0	0.9	0.9	0	0	0
Stock Based Compensation	1.7	1.0	0.4	0.2	45.4 K	1.4 K	22.4 K
Other Operating Activities	1.5	0	(0.9)	39.5 K	1.5	0.1	0.1
Change in Working Capital	(0.3)	(1.1)	1.3	0.4	0.3	4.7 K	24.9 K
Cash From Operations	(13.3)	(18.1)	(15.8)	(5.3)	(0.5)	(0.5)	(0.3)
INVESTING CASH FLOW
Capital Expenditures	0	35.6 K	(0.1)	(0.3)	0	0	0
Other Items	21.8 K	0	0	3 K	0	0	0
Cash From Investing Activities	21.8 K	35.6 K	(0.1)	(0.3)	0	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	0	0
Total Debt Repaid	0	0	0	0	1.2	0.5	0.6
Dividends Paid	30.6 K	0	0	0	0	0	0
Other Financing Activities	16.4	0	5.99 K	(0.8)	73.5 K	0	37.6 K
Cash From Financing Activities	16.4	15.9	5.99 K	25.5	1.1	0.5	0.5
CHANGE IN CASH
Net Change In Cash	3.0	(2.2)	(15.9)	20.0	0.6	8.51 K	0.2
FREE CASH FLOW
Free Cash Flow	(13.3)	(18.1)	(15.9)	(5.5)	(0.5)	(0.5)	(0.3)

Free